Nedghie Adrien, MPH, PhD

Nedghie Adrien, PhD, MPH (she/her) is an Assistant Professor at the Yale School of Public Health. Dr. Adrien earned her BA in Clinical Psychology from Tufts University and her MPH in Global Epidemiology from the Rollins School of Public Health at Emory University. She received her PhD in epidemiology from the Boston University School of Public Health and completed a postdoctoral fellowship in the CAUSALab at the Harvard T.H. Chan School of Public Health (HSPH) supported by the Training Program in Reproductive, Perinatal, and Pediatric (RPP) Life Course Epidemiology (T32HD104612).

Dr. Adrien is an epidemiologist with training in advanced epidemiologic methods and perinatal epidemiology. Her primary research focuses on the impact of dietary and pharmaceutical exposures during the periconceptional period on pregnancy and fetal outcomes. This research aims to address the paucity of information on the teratogenicity and safety of medications during pregnancy, and inform evidence for decisions around pharmacological treatment, which are currently largely based on perceptions of fetal risks.

She has also worked on vaccine studies and implementation of public health interventions. This work includes evaluating infection control practices in healthcare facilities during the 2014 - 2016 Ebola outbreak in West Africa, identifying gaps in the strategy to eliminate yellow fever, designing and implementing research studies to assess the effectiveness of introducing human papilloma virus (HPV) vaccine in routine immunization schedules in Senegal, and collaborating on a study using “real world” data from the COVID-19 US State Policy Database and from Institute of Health Metrics and Evaluation to evaluate mask wearing policies, adherence, and subsequent rates of COVID-19.

Dr. Adrien's most recent project focuses on leveraging administrative databases of millions of publicly insured pregnant people to identify individuals living with HIV, describe patterns of utilization of antiretroviral therapies during pregnancy, adherence to clinical guidelines and estimate the risk of congenital anomalies.